Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00959426 | A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers | PHASE1 | COMPLETED | 71 | — | — | Aug 1, 2009 | May 1, 2010 | Jun 7, 2010 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| PF-04620110 | EXPERIMENTAL | - |
| Placebo Comparator | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04620110 | DRUG | Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data. |
| Placebo | DRUG | Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria. |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18 and 55 years * Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight \>50 kg (110 lbs). Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, g...